WO2001064151A1 - Methodes et appareil de regulation thermique permettant de reguler l'administration transcutanee de substances medicales - Google Patents

Methodes et appareil de regulation thermique permettant de reguler l'administration transcutanee de substances medicales Download PDF

Info

Publication number
WO2001064151A1
WO2001064151A1 PCT/US2001/006390 US0106390W WO0164151A1 WO 2001064151 A1 WO2001064151 A1 WO 2001064151A1 US 0106390 W US0106390 W US 0106390W WO 0164151 A1 WO0164151 A1 WO 0164151A1
Authority
WO
WIPO (PCT)
Prior art keywords
heating
drag
patch
component
drug
Prior art date
Application number
PCT/US2001/006390
Other languages
English (en)
Inventor
Jie Zhang
Wade Hull
Larry Rigby
Theodore Stanley
Original Assignee
Jie Zhang
Wade Hull
Larry Rigby
Theodore Stanley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jie Zhang, Wade Hull, Larry Rigby, Theodore Stanley filed Critical Jie Zhang
Priority to EP01913151A priority Critical patent/EP1278496A4/fr
Priority to JP2001563051A priority patent/JP2003524508A/ja
Publication of WO2001064151A1 publication Critical patent/WO2001064151A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00544—Plasters form or structure
    • A61F2013/00646—Medication patches, e.g. transcutaneous

Definitions

  • the present invention is more specifically directed toward an apparatus and method for selectively heating and releasing medical substances from transdermal delivery systems and depot sites in or under a patient's skin or from inj ected or implanted controlled release systems.
  • Transdermal drug delivery affords users and patients distinct advantages over other delivery methods and techniques. Patients prefer transdermal administration in some cases because of the ease of administration and because transdermal drugs are delivered noninvasively. Care givers also appreciate the ease of administration and the ability to deliver a drug over a long period of time. Transdermal delivery in many cases avoids first pass elimination of drugs. Because of these advantages, transdermal drug delivery has grown in popularity and interest in studying transdermal drug delivery has increased. Transdermal drug delivery occurs as a drug formulation is brought into contact with a patient's skin. In transdermal drug delivery, it often occurs that some of the drug gets stored in skin and sub-skin tissues after penetrating the skin.
  • transdermal drug delivery is capable of rapidly responding to changing needs in a patient.
  • the time it takes for the drug to be delivered from the drug formulation to the skin, be absorbed into the skin and surrounding tissues and from there absorbed into the systemic circulation and delivered throughout the systemic circulation has been seen as a barrier for rapid response or modification of the drug circulation in systemic circulation.
  • techniques such as patient controlled analgesia (PCA) have not been attempted using transdermal drugs.
  • PCA patient controlled analgesia
  • Patient controlled analgesia may require the ability of the patient to choose when a particular dose will be delivered, the ability of the care giver to set or prescribe the amount that will be delivered rapidly on demand, and the ability to prevent or lock-out the patient from excessively self-dosing.
  • transdermal drug delivery system which can rapidly respond to a patient's changing needs, that could deliver an additional drug dose quickly (referred to as bolus drug hereafter), and that could allow a patient to control the delivery of the additional drug on demand that can allow the caregiver to prescribe how much extra drug the patient can obtain from self dosing, and that could allow the caregiver to set "lock-out" times to prevent the patient from excessively self-dosing.
  • Lock-out time is the time period in which no extra drug is delivered even if the patient triggers the self-dosing mechanisms.
  • the present invention also provides for extended duration of drug delivery limited only by the supply of drug and availability of electric current.
  • the present invention also provides the ability to vary intervals at which extra drug is delivered and the length of time by which the drag is delivered.
  • the present invention also provides the ability to let the caregiver to set "lock-out" time. This can be accomplished through use of a microprocessor in conjunction with the electric heating component.
  • the present invention provides the ability to respond quickly to the patient's need and provide the patient a drug dose on demand in a safe and effective manner. By using the present invention s described in the methods herein, a patient can self-administer analgesia (PCA) or other drugs where appropriate.
  • PCA analgesia
  • the present invention allows the user a greater variety of methods of use and provides additional reliability such as more precise control over the areas, either the temperatures at which they are heated and the duration for which they are heated.
  • the present invention provides a variety of temperature profiles.
  • the present invention does not require the continued replacement of the heating element.
  • the methods and apparatus presented in this invention may provide extra drug from controlled release formulations or devices implanted or injected into the skin or sub-skin tissues.
  • the user may create a "depot site” by implanting or injecting drag into the skin and sub-skin tissues.
  • an extra bolus of drag can be delivered into the patient' s body by heating the skin and sub-skin tissues under a transdermal drag delivery system that has been on the skin for sufficient time to establish a depot site (or "depot") of the drug in said tissues.
  • a depot is formed when part of the drag delivered across the skin gets absorbed into the skin and/or sub-skin tissues, such as fatty tissues, and gets stored there.
  • heat is used to rapidly drive drug from the depot into the systemic circulation by mechanisms such as increased blood flow.
  • transdermal drug delivery Prior to the present invention, those skilled in the art understood transdermal drug delivery to be a slow process, with slow onset, slow offset, and relatively smooth delivery rates.
  • recent experiments with transdermal fentanyl patches using the present invention revealed that blood drag concentrations can rise rapidly and significantly following heating.
  • serum fentanyl concentrations increased very rapidly (within 5-10 min) and significantly (>50%) following the commencement of the heating and stayed elevated for an extended period of time.
  • a serum fentanyl concentration increase (more than 50% within 5-10 min.) using the present invention is very surprising.
  • These results indicate that releasing a significant portion of fentanyl stored in the depot into the systemic circulation by heating can be a rapid process, and can be achieved with relatively brief heating.
  • the results of recent studies show dramatic improvements in drag delivery using oxidation heating the drag in the sub-skin depot.
  • the present invention employs the principle of heating the drag in the sub-skin depot in a precisely regulated PCA environment.
  • the present invention provides new methods and apparatus to rapidly deliver extra drug to the patient to accommodate his/her changing needs. For some drags, a relatively short heating period is all that is required to significantly increase serum drug concentrations.
  • a compact battery-powered heating source/control apparatus with various important and useful features is provided.
  • a highly accurate, reliable, and precise control apparatus may be necessary to safely and effectively deliver the bolus drug from sub-skin tissues by heating, since the drag release from depot can be very sensitive to the temperature increase.
  • the temperature control of the heating as well as heating area must be very precise in order to accurately deliver the desired amount of bolus drugs. For example, it is believed that an increase of 15-20 percent in serum fentanyl levels is sufficient to treat a typical episode of breakthrough cancer pain. A much higher increase may not only be unnecessary, but may also be dangerous.
  • the present invention provides novel methods and apparatus for using heating to deliver bolus drags from sub-skin depot sites in a highly precise, controllable, and convenient way.
  • the present invention comprises three essential parts: a drag depot site (which may be produced by transdermal delivery or injection or implantation ), a heating component to generate heat for heating the drug depot site and/or surrounding tissues, and a control component that controls the heating temperature on the depot site.
  • the heating component is preferably an electric heating component.
  • the electric heating component and control component are connected by electric wires.
  • the method of the present invention comprises the steps of creating a depot site beneath a patient's skin and selectively applying controlled heat to the depot site to release a portion of the drug from the depot site to the systemic circulation.
  • the present invention also relates to methods and apparatus for using the heating component and the control component to heat the skin under a drug patch in the initial phase of the patch application to increase skin permeability in order to significantly shorten the onset time of the drug patch. Since there is little depot in the initial phase of the patch application, the main effect of the heating is increasing skin permeability, rather than release drug from depot.
  • the control component may have a mechanism that allows the patient to trigger the delivery of a pre-determined amount of bolus drug from the depot and the drag patch.
  • a button on the control component e.g., a PCA button
  • the pre-programmed control component sends an electric current with pre-determined magnitude through wires to the heating component for a predetermined length of time.
  • the magnitude and the duration of the current are such that it produces a temperature increase at the skin for a duration that releases a pre-determined amount of the drag from the depot into the systemic circulation.
  • the magnitude of the current may be designed to produce different heating temperature vs. time profiles to accommodate different needs.
  • FIG. 1 shows some examples of the temperature vs. time profiles.
  • the control component may also have a mechanism to allow the physician or care giver to choose from several pre-programmed heating temperature profiles which correspond to different amounts of extra drag.
  • the physician may choose a profile that heats for five minutes at a predetermined temperature for treating a patient suffering from episodes of mild breakthrough pain, and a profile that heats for fifteen minutes at the same temperature for another patient who usually suffers from episodes of more severe breakthrough pain.
  • the physician may choose a profile that increases the temperature at the patch by 2°C from the unheated temperature for ten minutes for the first patient and another profile with 4°C by ten minutes for the latter patient.
  • a simpler version of the apparatus may have settings in the control component that correspond to pre-determined electric power and heating time combinations. Each setting delivers a different pre-determined amount of heating energy (in the form of different heating temperature and duration) to the skin site.
  • the temperature of the skin is not monitored. But the electric power in each setting is pre-determined to be safe to the skin.
  • This simpler version does not have the temperature sensor, monitoring, and feedback system, so the cost is lower. This may increase the feasibility of a disposable heating component.
  • the control component also may have the mechanism to allow the physician to set "lockout” times, which is the length of time in which the device generates no heat even if the patient tries to trigger the delivery of extra drag.
  • the "lockout” feature is commonly used in PCA devices for preventing drug overdose. It may also serve the purpose of allowing sufficient time to re-fill the depleted depot in the tissues under the drug patch.
  • the control component may have a mechanism that receives a temperature signal from a temperature sensor proximate to the skin or drug patch and adjusts the electric current to the heating component accordingly.
  • the heating component is capable of generating heat when supplied with electric current. It may also have a temperature sensor that can sense the temperature at the drug patch or skin and feed it back to the control component to regulate the heating temperature.
  • the heating component may also have a layer of thermal insulating material on the side not in contact with the drug patch for minimizing heat loss and maintaining a more stable temperature at the skin, even when there is no heating.
  • Figure 1 shows some examples of the temperature vs. time profiles.
  • Figure 2 is a heating component with means for affixing
  • Figure 3 is a heating component in the form of exothermic oxidation heating patch with a heating area covering a different fraction of the drag patch area
  • Figure 4 shows a fentanyl patch sub-heating elements accommodating an electric heating apparatus with sub-heating elements
  • Figure 5 shows a graph of serum fentanyl concentration changes caused by heating.
  • Example 1 The surprising results of the controlled heat induced fentanyl bolus delivery were observed in a study of controlled heat-induced bolus delivery of fentanyl from a dermal fentanyl patch and drag depot in tissues under the patch.
  • Concentrations of fentanyl in the serum samples were determined by aradioimmunoassay method.
  • the heating patch had a heating area of approximately 40 cm 2 .
  • Serum fentanyl concentrations of the 5 subjects who completed both arms and that of another subject who completed only part are shown in Table I.
  • the heating patches had a bottom wall (made of plastic tape, with the adhesive side facing away from the top wall), a top wall (made of plastic tape, with the adhesive side facing the bottom wall), and a heat-generating medium in a thin tissue bag.
  • the edge of the top wall was adhered on the edge of the bottom wall to form a closed space between the walls.
  • the tissue bag resided in the space.
  • the top wall had pre-determined number of holes with predetermined size.
  • the heat-generating medium comprised activated carbon, iron powder, fine wood powder, salt, and water.
  • the heating patch was stored in an air-tight pouch immediately after manufacturing. Shortly before use, the heating patch was removed from the pouch. Oxygen in ambient air flows into the heat- generating medium via the hole in the top wall to cause heat-generating oxidation reaction.
  • the heating temperature and duration are determined by the size and number of the holes in the top wall, as well as the quantity and composition of the heat-generating medium. For example, the heating patch that lasted approximated 4 hours had more heat- generating medium than the one that lasted about 1 hour.
  • transdermal drag delivery is a slow process, with slow onset, slow offset, and relatively smooth delivery rates. Therefore, a serum fentanyl concentration increase of 60 percent or more within 5-10 min is very surprising. These results suggest that a significant portion of fentanyl stored in the depot can be rapidly delivered to the systemic circulation by heating the depot site. This suggests that precise amount of bolus drag may be delivered into the systemic circulation by a short but precise heating of the patch and sub-patch tissues.
  • the heating patch had a heating area of approximately half the heating area described in Example 1.
  • the apparatus of the present invention has a heating component and a control component.
  • the two components are connected by wires.
  • the two components are connected by a detachable connector.
  • the heating component comprises a substantially two dimensional resistor heating element that can generate heat when supplied with electricity.
  • the size and shape of the heating element may vary. If the heating element is attached to a transdermal drag delivery patch, the area of the heating component may be smaller, the same, or larger than the area of the drug patch, depending on the need. For example, a larger-than-drag-patch heating component may be needed to also heat the tissues surrounding the drag patch if a maximum speed of releasing the drag from the depot is desired.
  • the heating component may have a temperature sensor in contact with the drug patch such that the temperature sensor can sense the temperature and feed it back to the control component via the wires to regulate the temperature by controlling the electric current or voltage output to the heating element.
  • the heating component may be attached to the drag patch using various means such as hook and loop attachments, adhesive and pouches. Means to detach from the drug patch without removing the drag patch from the skin may also be provided.
  • the heating component may have a layer of insulating material (i.e. foam tape) on the side of the heating element that is not in contact with the drug patch (optional).
  • a layer of insulating material i.e. foam tape
  • the insulating layer can minimize the temperature variation due to outside environment and minimize the electric power needed to achieve desired heating temperature.
  • the heating element may be disposable or reusable.
  • the control component provides a mechanism for delivering different heating temperatures/durations, which corresponds to different bolus drag amounts.
  • This mechanism can be in the form of a multi-position dial switch. Each position on the dial switch corresponds to a pre-programmed heating temperature-time profile having a predetermined heating temperature and duration.
  • the heat can release a predetermined amount of drag from the depot under the drag patch.
  • the control component also may optionally comprise a mechanism for regulating heating temperature based on the signal from the temperature sensor.
  • the temperature sensor may take a skin temperature measurement and/or a patch temperature measurement before heating.
  • the control component then delivers adequate electric current or voltage (as a function of time) to the heating element to produce the pre- programmed temperature increase vs. time profile.
  • the sensor may continue to measure the temperature in the process of heating and feed it back to the control component to assure that the actual temperature is in the predetermined range. It is understood that the amount of bolus release from the depot may be more related to the change in the skin temperature from unheated to heated temperatures and heating duration than the absolute skin temperature.
  • the temperature feed back system may not be needed, and the positions in the dial switch only need to correspond to different predetermined amounts of heating energy (in the form of different predetermined magnitudes of electric current or voltage and/or durations of the electric current or voltage).
  • the electric current or voltage represented by each dial switch position must be pre-determined to avoid over heating the skin.
  • a temperature sensor may still be used in a mechanism that will automatically turn off the electric current or voltage if a dangerously high temperature is sensed by the temperature sensor. This may be an important safety feature.
  • the control component has a delivery button. When the button is pushed, the control component delivers one episode of electric current or voltage to the heating component according to the setting on the dial switch (mentioned above).
  • the setting may be predetermined by or selected by the physician or health care giver.
  • the heating component then heats the drag patch skin and/or depot site for a pre-determined period of time with a pre-determined temperature profile.
  • a pre-determined amount of bolus drug is delivered after the delivery button is pushed.
  • the control component also has a lockout mechanism that allows the physician to select a period of time in which the control component delivers no electric current to the heating element even if the delivery button is pushed.
  • This may be in the form of a dial switch with several positions, such as 5, 10, 15, 20, 30, 45, 60 minutes. For example, if the dial switch is set at 10 minute, the apparatus will generate no electric current for a period of 10 minutes after the last bolus, even if the delivery bottom is pushed. This is necessary to minimize the overdose risk and give enough time for the drug depot in the tissues under the drag patch to re-fill after last bolus.
  • Example 4 The device is similar to that of Example 3, except that the heating component has several independent sub-heating elements, as shown in Figures 3 and 4, each covering a fraction of the area (sub-area) of the drag patch.
  • the drag patch is a transdermal fentanyl delivery patch.
  • the control component also has the ability to activate one of more of the sub-heating elements at a time and thereby selectively heating one or more sub-areas .
  • the heating component has four sub-heating elements.
  • the control component is designed so that when the delivery button (PCA button) is pushed for the first time, only the first sub-heating element is activated to heat about 25 percent of the fentanyl patch area (first sub-area) to a pre-determined temperature for a pre-determined time.
  • Fentanyl in the depot in tissues under the heated area is then quickly released into the systemic circulation to treat breakthrough pain.
  • the control component activates the second sub-heating element, and so on.
  • the first sub-heating element is activated again.
  • the depot under the first sub-heating element is re-filled.
  • only a fraction of the total fentanyl depot is released into the systemic circulation at a time. This may minimize the overdose risk and allow each sub-depot time to re-fill after the depletion. Itis estimated that to effectively treat break through pain, a 15-20 percent increase in serum fentanyl concentration might be necessary and sufficient.
  • heating the entire patch and the corresponding depot areas and surrounding skin area yields a 70 percent increase in serum fentanyl concentration within 10 minutes. Therefore, it is possible and may be necessary that only a fraction of the fentanyl patch and corresponding depot site needs to be heated to provide sufficient additional fentanyl to treat breakthrough pain.
  • Example 5 a device similar to that in Example 3 or 5 is used, but the device further comprises the feature that the heating component is an integral part of the drug patch. All the wires from the heating component (from each of the sub-heating elements, temperature sensor, etc.) are integrated into a connector capable of accommodating a matching connector with wires from the control component.
  • the patient wears the heating component-drug patch combination and enjoys the benefit of thermal insulation from the heating component.
  • the patient hooks the heating component to the control component via the connectors and pushes the delivery button on the control component.
  • the patient may disconnect the control component from the heating component.
  • Example 6 the device is similar to that in Example 3 or 4, but further comprises the feature that the heating component is not an integral part of the drag patch but is connected to the control component by wires.
  • the device comprises means for releasably affixing the heating component to the drag patch.
  • the heating component and the drag patch may have areas with matching loop and hook fasteners or a pouch attachment.
  • the patient wears the drag patch alone when there is no need for bolus dose.
  • the need for bolus dose arises, the patient places the heating component onto the drug patch, the means for releasably affixing holds the heating component on the drug patch. The patient then pushes the delivery button on the control component to obtain the extra drug.
  • the patient can remove the heating component from the drag patch without having to remove the drug patch.
  • the means for affixing on the heating component and the drag patch can be designed so that there is only one way to affix the heating component onto the drag patch. By doing so, the sequential sub-area heating feature described in Example 3 may be used. Some of those means are shown in Figures 2 and 4.
  • a heating component generates heat by chemical reaction such as by oxidation of iron powder.
  • the heating component and the drug patch are designed so that there is only one way to affix the heating component on to the drug patch.
  • the heating component in the form of a patch, comes in several different designs, each with a heating area covering a different fraction of the drag patch area as shown in Figure 3.
  • the heating patches are in a dispenser that only allows the user to obtain the heating components according to a pre-arranged order. For example, the heating patches are stacked in a dispenser which only allow the user to take the top one before taking the next one.
  • the pre-arranged order is such that the fractions of the drug patch area to be heated are in sequential order. In this way, the user activates the fractions of the depot area in a sequential order.
  • the benefits of selectively heating a portion of the patch and depot site as discussed in Example 3 can thereby be obtained using an exothermic, oxidation heating element.
  • a heating component combination design similar to that shown in Fig.4 may also be utilized here.
  • the heating component (in the form of a disc) has four different designs, each with a heating area capable of covering a different fraction of the drug patch area.
  • the heating disc has a wide side and a narrow wide, and the pouch on the back of the drag patch has three closed sides and one open side that can only allow the heating disc to slide in narrow side first.
  • the heating discs are stored in the dispenser as discussed above.
  • the sequential heating of the different fractions of the drag patch area can be achieved in the similar way as discussed above.
  • Example 8 In this example, a heating device similar to the device in Example 3 with several sub-heating elements has a heating component that can be positioned on the fentanyl patch in only one orientation, so that the sub-skin areas under the patch can be heated in the desired order.
  • Fig. 4 describes a combination of a pouch on the back of the fentanyl patch and a heating disc that allows only one way to insert the disc into the pouch.
  • the disc has a wider side and a narrower side.
  • the pouch is closed on three sides but has an open mouth
  • transdermal fentanyl patch is discussed above with this pouch- heating disc combination, it should be pointed out that similar methods/apparatus may also be used with other transdermal drag patches.
  • Drags may be used in the systems of this invention. They include: analgesics, anesthetics, anti-arthritis drags, anti-inflammatory drags, anti-migraine drags, cardiovascularly active drags, smoke cessation drags, hormones.
  • Other potential drags include, but are not limited to: androgen, estrogen, non-steroidal anti-inflammatory agents, anti-hypertensive agents, analgesic agents, anti-depressants, antibiotics, anti- cancer agents, local anesthetics, antiemetics, anti-infectants, contraceptives, anti-diabetic agents, steroids, anti-allergy agents, anti-migraine agents, agents for smoking cessation, and anti-obesity agents.
  • Specific drags can include without limitation nicotine, testosterone, estradiol, nitroglycerin, clonidine, dexamethasone, wintergreen oil, tetracaine, lidocaine, fentanyl, sufentanil, alfentanil and other potent mu-receptor agonists, progestrone, insulin, Vitamin A, Vitamin C, Vitamin E, prilocaine, bupivacaine, sumatriptan, scopolamine and dihydroergotamine.
  • Example 9 The present invention may also comprise a non-invasive PCA fentanyl delivery system for treating post-surgical pain and the method of using it.
  • the system has three components: a transdermal fentanyl patch (preferably with means to accommodate a heating component, similar to that shown in Fig.4), a control component and a heating component.
  • the control component and the heating component are connected by conductive wires.
  • the fentanyl patch is capable of delivering fentanyl through passive transdermal permeation.
  • the heating unit and the control component are similar to that in Example 4, 5, 6 and 8.
  • the device can be powered by both AC source or battery (batteries).
  • the physician places the fentanyl patch on the skin of the patient at a time point during or after the surgery and selects the settings on the control component so that all-sub heating elements of the heating component heat the skin under them to about 40-42 C for 3.5 hours .
  • the control component has a PCA button and a set of dial switches (Bolus Dial), with each position on the Bolus Dial corresponding to a pre-determined bolus dose.
  • the control component When the PCA button is pushed, the control component sends an electric current or voltage to particular sub-heating element(s) of the heating component.
  • the magnitude and duration of the current or voltage, as well as which sub-heating element(s) to activate, are determined by the setting on the Bolus Dial.
  • the control component sends no current or voltage to the heating component if the PCA button is pushed within the lockout time from last bolus dose.
  • the lockout time is selected with another dial switch (Lockout Time Dial).
  • the physician may set the control component such that the patient can push the delivery button (a PCA button) to obtain a bolus dose when he/she feels the need to obtain more analgesic than the baseline delivery provided by the passive permeation of the patch.
  • a PCA button a PCA button
  • the control component allows the physician to select the proper bolus dose and proper lockout time.
  • the control component may have several possible embodiments for relating the settings on the Bolus Dial to different predetermined bolus doses.
  • each position on the Bolus Dial may correspond to a number of sub-heating elements to be activated.
  • the heating component may have twenty sub-heating elements, and heating one of them to a predetermined temperature for a predetermined duration delivers one unit of the drag in the depot into the systemic circulation. Therefore, if the switch position of the Bolus Dial is at "1 unit" when the PCA button is pushed, one sub-heating element is supplied with pre-selected electric current or voltage for a predetermined duration. If the switch position is at "2 unit" when the PCA button is pushed, two heating elements are supplied with the current or voltage, and so on.
  • the sub-heating elements to be activated are in a pre-determined sequential order if the PCA button is pushed multiple times (see Examples 4 and 8 for details and rationale)
  • each position on the Bolus Dial corresponds to a different heating time.
  • the "1 unit” position heats 5 sub-heating elements for 1 minute
  • the "3 unit” position heats 5 sub-heating elements for 3 minutes, and so on.
  • the amount of bolus may not be linearly proportional to the duration of heating because more drug might be released from the depot per unit time of heating at the beginning of the heating when there is more drag in the depot. Therefore, a 3 unit bolus may require three more times the heating time than a 1 unit bolus. The actual heating duration for each bolus dose needs to be determined by experiments.
  • control unit may also be programmed such that it is automatically set into the PCA mode after the initial 3-4 hour heating.
  • the control unit may also have the mechanism to selectively heating a number of the sub-heating elements continuously throughout part or all of those post- surgical days.
  • This mechanism can be in the form of another set of dial switches on the control unit (Baseline Rate Dial), with each position on the Baseline Rate Dial corresponds to continuously heating a selected number of sub-heating elements. For example, heating the skin to about 42 C may increase transdermal fentanyl delivery rates by a factor of about 4.
  • a patient may receive satisfactory analgesia to control his post- surgical pain by the system without heating (after the initial heating to shorten the onset time).
  • Another patient may need 60% more fentanyl to control the post-surgical pain after the initial heating.
  • the physician can select a position on the Baseline Rate Dial that causes 4 of the 20 sub-heating elements to continuously heat.
  • the result is that the patient gets 160% of the delivery rate of an unheated patch.
  • the physician may also change the setting on the Baseline Rate Dial to change the number of sub-heating elements that continuously heat if the initial setting is too high or too low, or the patient's need changes. Therefore, this design allows the physician to precisely control the baseline drug delivery rates for each patient and make adjustments when necessary.
  • the above apparatus and method have several important advantages over the state of the art.
  • Current passive transdermal fentanyl patches such as Duragesic patches, are not suitable for post-operative pain control for several reasons, including long onset time (12-18 hours) and the lack of the ability to adjust fentanyl delivery rates either by the physician or the patient . They also don't have important features such as PCA dosing and lockout time.
  • the above apparatus will significantly shorten the onset time, so that therapeutic levels of blood fentanyl can be established before the analgesia from the surgery runs out.
  • the system lets the physician to select a proper PCA bolus dose for a particular patient, and allows the patient to obtain PCA doses by pushing the PCA button.
  • the apparatus delivers fentanyl at a baseline rate and lets the physician make adjustments to the baseline delivery rate in a timely manner for each patient and to accommodate changing needs.
  • This system has most of the important features of a modern PCA pump (baseline delivery, adjustable baseline delivery rates, adjustable bolus doses, lockout times), but also has the added advantage of being non-invasive.
  • the above system is not limited to using fentanyl as the analgesic. Any drag that can be delivered transdermally to provide sufficient analgesia may be used in the above system. These drags include sufentanil, alfentanil, and other potent mu-receptor agonists.
  • Example 10 The methods and apparatus are similar to that described in Example 3 through 8, except that the drag patch is a transdermal nicotine patch for smoke cessation. When the user has increased desire to smoke, he can release extra nicotine from the sub-patch depot using the apparatus.
  • a controlled release formulation comprising fentanyl and a controlled release hydrogel is inj ected into the sub-skin tissues of a patient to control post-surgical pain.
  • the controlled release formulation is within 0.5 cm from the skin surface, so that heating of the skin can increase the temperature at the formulation.
  • the fentanyl release rate is increased by heating because the heating increases blood circulation surrounding the formulation and/or increases the erosion speed of the formulation.
  • This controlled release system provides sufficient fentanyl delivery rates to treat baseline pain of an average patient. If a particular patient needs more analgesic to control his pain, the physician may place the heating component of a device similar to that in Example 9
  • control component and heating element but no transdermal patch
  • Example 12 Similar to that in Example 11, except that in this case the controlled release formulation is used to treat cancer pain and the drag is sufentanil.
  • the controlled release formulation is designed to deliver sufentanil at sufficient rates to treat baseline cancer pain for at least several months.
  • the patient needs extra sufentanil to treat breakthrough cancer pain, he/she uses the apparatus similar to that in Example 9 and 11 to obtain the bolus dose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

La présente invention concerne des méthodes et un appareil utilisant la régulation thermique afin de réguler la libération régulée et transcutanée qui permet d'administrer rapidement du fentanyl, d'autres analgésiques et substances à un patient. Une méthode de cette convention consiste à placer un médicament sous la peau d'un patient dans une forme retard. Un composant chauffant est placé près du site de forme retard et génère de la chaleur dans ledit site et à sa proximité. Un composant de régulation connecté au composant chauffant est utilisé pour réguler la quantité de la chaleur générée par le composant chauffant et la durée pendant laquelle ladite chaleur est générée.
PCT/US2001/006390 2000-02-29 2001-02-28 Methodes et appareil de regulation thermique permettant de reguler l'administration transcutanee de substances medicales WO2001064151A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01913151A EP1278496A4 (fr) 2000-02-29 2001-02-28 Methodes et appareil de regulation thermique permettant de reguler l'administration transcutanee de substances medicales
JP2001563051A JP2003524508A (ja) 2000-02-29 2001-02-28 医薬物質の経皮輸送を制御するための調節加熱

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18591300P 2000-02-29 2000-02-29
US60/185,913 2000-02-29

Publications (1)

Publication Number Publication Date
WO2001064151A1 true WO2001064151A1 (fr) 2001-09-07

Family

ID=22682935

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006390 WO2001064151A1 (fr) 2000-02-29 2001-02-28 Methodes et appareil de regulation thermique permettant de reguler l'administration transcutanee de substances medicales

Country Status (3)

Country Link
EP (1) EP1278496A4 (fr)
JP (2) JP2003524508A (fr)
WO (1) WO2001064151A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058678A2 (fr) * 2001-01-23 2002-08-01 Lts Lohmann Therapie-Systeme Ag Dispositifs et procedes permettant l'application transdermique assistee par impulsions thermique, de substances actives
WO2011160604A3 (fr) * 2010-06-25 2012-02-16 Royal Natural Medicine, S.R.O. Bandage multicouche
EP2574275A3 (fr) * 2004-03-22 2013-06-26 BodyMedia, Inc. Dispositif de surveillance de température non invasif

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400685D0 (sv) * 2004-03-19 2004-03-19 Pfizer Health Ab Means for transdermal administration of nicotine
WO2018004182A1 (fr) * 2016-06-30 2018-01-04 서울대학교 산학협력단 Dispositif de biodétection et dispositif de libération de médicament
KR101843265B1 (ko) * 2016-06-30 2018-03-29 서울대학교산학협력단 약물 전달 장치
KR101847984B1 (ko) * 2016-07-25 2018-04-11 서울대학교산학협력단 약물 전달 장치
KR101942169B1 (ko) * 2017-01-02 2019-01-24 가천대학교 산학협력단 마이크로 니들 장치

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963360A (en) * 1988-02-12 1990-10-16 Albert Argaud Exothermic package body having a layer containing a medicinal component

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5835233Y2 (ja) * 1980-11-10 1983-08-08 薫 長谷部 植物のエキスを用いた治療器具
JPS58108826U (ja) * 1982-01-19 1983-07-25 小林　勝美 温湿布補助具
US4830855A (en) * 1987-11-13 1989-05-16 Landec Labs, Inc. Temperature-controlled active agent dispenser
JPH06197924A (ja) * 1992-12-28 1994-07-19 Kimura Giken:Kk 温熱治療器
US5658583A (en) * 1995-07-28 1997-08-19 Zhang; Jie Apparatus and methods for improved noninvasive dermal administration of pharmaceuticals
US5980934A (en) * 1997-05-19 1999-11-09 Motorola, Inc. Transdermal delivery apparatus
US6001090A (en) * 1998-02-09 1999-12-14 Lenhart; Douglas Thermal pharmaceutical delivery system
JP3049707B2 (ja) * 1998-04-03 2000-06-05 花王株式会社 水蒸気発生体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963360A (en) * 1988-02-12 1990-10-16 Albert Argaud Exothermic package body having a layer containing a medicinal component

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1278496A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058678A2 (fr) * 2001-01-23 2002-08-01 Lts Lohmann Therapie-Systeme Ag Dispositifs et procedes permettant l'application transdermique assistee par impulsions thermique, de substances actives
WO2002058678A3 (fr) * 2001-01-23 2002-12-05 Lohmann Therapie Syst Lts Dispositifs et procedes permettant l'application transdermique assistee par impulsions thermique, de substances actives
EP2574275A3 (fr) * 2004-03-22 2013-06-26 BodyMedia, Inc. Dispositif de surveillance de température non invasif
WO2011160604A3 (fr) * 2010-06-25 2012-02-16 Royal Natural Medicine, S.R.O. Bandage multicouche

Also Published As

Publication number Publication date
EP1278496A1 (fr) 2003-01-29
JP2006326337A (ja) 2006-12-07
JP2003524508A (ja) 2003-08-19
EP1278496A4 (fr) 2007-01-24

Similar Documents

Publication Publication Date Title
US6955819B2 (en) Methods and apparatus for using controlled heat to regulate transdermal and controlled release delivery of fentanyl, other analgesics, and other medical substances
US6245347B1 (en) Methods and apparatus for improved administration of pharmaceutically active compounds
US6756053B2 (en) Controlled heat induced rapid delivery of pharmaceuticals from skin depot
US6284266B1 (en) Methods and apparatus for improved administration of fentanyl and sufentanil
EP1117357B1 (fr) Dispositifs servant à ameliorer l'administration de composes actifs sur le plan pharmaceutique
US6261595B1 (en) Transdermal drug patch with attached pocket for controlled heating device
JP2005501014A5 (fr)
US20200008973A1 (en) Apparatus and method for using a portable thermal device to reduce accommodation of nerve receptors
JP2006326337A (ja) 医薬物質の経皮輸送を制御するための調節加熱
JPH11510075A (ja) 改善された非侵襲性の薬剤皮膚投与のための装置及び方法
US20020114827A1 (en) Methods and apparatus for improved administration of analgesics
WO2011159317A1 (fr) Procédé et appareil pour stimulus vibratoire, tactile et autre localisé pour diminuer la douleur associée à des injections pour des procédures chirurgicales mineures et des traitements cosmétiques au laser
WO2010088914A1 (fr) Dispositif de régulation du débit sanguin sous-cutané
JP2022507660A (ja) 温度によって調節される経皮薬剤送達システム

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AG BZ CA CN CO DZ JP MZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 563051

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001913151

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001913151

Country of ref document: EP